organization · Reporting owner
GV 2021 GP, L.P.
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gitlab Inc.GTLB · Entity 3663 | Member of 10% Group | May 05, 2023 | May 09, 2023 |
| Prime Medicine, Inc.PRME · Entity 5281 | 10% owner | August 01, 2025 | August 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gitlab Inc.
Report date May 05, 2023 · Filed May 09, 2023
Jointly reported with GV 2021 GP, L.L.C., GV 2021, L.P., Alphabet Inc.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectBy GV 2021, L.P. | 2,647,312 |
Reported balance
After 2023-05-05 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-05-05 · Purchase · Acquired 7,286 · Balance 2,647,312 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.86 to $27.00, inclusive. The reporting persons undertake to provide to GitLab Inc., any security holder of GitLab Inc., or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1 of this Form 4. F2: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "Partnership"). GV 2021 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2021 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the Partnership. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.86 to $27.00, inclusive. The reporting persons undertake to provide to GitLab Inc., any security holder of GitLab Inc., or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1 of this Form 4.
F2: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "Partnership"). GV 2021 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2021 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the Partnership. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Prime Medicine, Inc.
Report date August 01, 2025 · Filed August 05, 2025
Jointly reported with GV 2021 GP, L.L.C., GV 2021, L.P., Alphabet Inc.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy GV 2021, L.P. | 3,262,440 |
Reported balance
After 2025-08-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-08-01 · Purchase · Acquired 1,500,000 · Balance 3,262,440 F1: Represents shares purchased in connection with an underwritten public offering of the Issuer's Common Stock that closed on August 1, 2025. F2: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). The general partner of the 2021 Partnership is GV 2021 GP, L.P. (the "2021 GP"). The general partner of the 2021 GP is GV 2021 GP, L.L.C. ("GV 2021 LLC"). The sole member of GV 2021 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the 2021 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares purchased in connection with an underwritten public offering of the Issuer's Common Stock that closed on August 1, 2025.
F2: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). The general partner of the 2021 Partnership is GV 2021 GP, L.P. (the "2021 GP"). The general partner of the 2021 GP is GV 2021 GP, L.L.C. ("GV 2021 LLC"). The sole member of GV 2021 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the 2021 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ethos Technologies Inc.
Report date July 27, 2026 · Filed July 29, 2026
Jointly reported with GV 2019 GP, L.L.C., GV 2019 GP, L.P., GV 2019, L.P., GV 2021 GP, L.L.C., GV 2021, L.P., Alphabet Inc.
Section 16 reporting ended · disclosed 2026-07-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectBy GV 2019, L.P. | 2,443,425 |
Last balance in matching sequence
After 2026-07-28 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-27 · Other · Disposed 196,931 · Balance 2,561,563 F1: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the GV 2019, L.P. ("2019 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2: The securities reported in this row are directly beneficially owned by the 2019 Partnership. GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Row 3 · 2026-07-28 · Other · Disposed 118,138 · Balance 2,443,425 F1: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the GV 2019, L.P. ("2019 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2: The securities reported in this row are directly beneficially owned by the 2019 Partnership. GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Alphabet Holdings LLC | 0 |
Reported balance
After 2026-07-27 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-07-27 · Sale · Disposed 196,931 · Balance 0 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.21 to $19.795, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4. F4: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Exchange Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Alphabet Holdings LLC | 0 |
Reported balance
After 2026-07-28 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-07-28 · Sale · Disposed 118,138 · Balance 0 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.45 to $19.19, inclusive. F4: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Exchange Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy GV 2021, L.P. | 571,907 |
Reported balance
Holding disclosure · report date 2026-07-27 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 571,907 F6: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). GV 2021 GP, L.P. (the "2021 GP") is the general partner of the 2021 Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the 2021 GP. Alphabet Holdings is the sole member of GV 2021 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2021 Partnership. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the GV 2019, L.P. ("2019 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
F2: The securities reported in this row are directly beneficially owned by the 2019 Partnership. GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.21 to $19.795, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4.
F4: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Exchange Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.45 to $19.19, inclusive.
F6: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). GV 2021 GP, L.P. (the "2021 GP") is the general partner of the 2021 Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the 2021 GP. Alphabet Holdings is the sole member of GV 2021 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2021 Partnership. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2023 Filed Jun 13, 2023 20:20 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 15,672 | $14.48 | $226,983.84 |
DisclosureSEC source: 0001209191-23-036666 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.925, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:20 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 15,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036666 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,302,748 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:24 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 5,000 | $15.74 | $78,686.50 |
DisclosureSEC source: 0001209191-23-035849 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.1401 to $16.0950, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:24 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035849 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,318,420 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:24 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 15,000 | $16.92 | $253,870.50 |
DisclosureSEC source: 0001209191-23-035849 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.77 to $17.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:24 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035849 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,323,420 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 29,975 | $17.02 | $510,165.51 |
DisclosureSEC source: 0001209191-23-035068 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.90 to $17.10, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 29,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035068 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,338,420 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 22,434 | $16.70 | $374,611.91 |
DisclosureSEC source: 0001209191-23-035068 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 to $16.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 22,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035068 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,368,395 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 471 | $14.75 | $6,948.85 |
DisclosureSEC source: 0001209191-23-033697 · doc4.xml · nonDerivative · entry 5 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $14.78, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 44,752 | $14.35 | $642,244.90 |
DisclosureSEC source: 0001209191-23-033697 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 471 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.75 to $14.74, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 45,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033697 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,390,829 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 16,633 | $13.65 | $227,003.86 |
DisclosureSEC source: 0001209191-23-033697 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.52 to $13.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnotes 6 and 7 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 16,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033697 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,436,052 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 30, 2023 Filed May 31, 2023 20:15 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 16,805 | $13.70 | $230,240.26 |
DisclosureSEC source: 0001209191-23-033107 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.505 to $13.86, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 30, 2023 Filed May 31, 2023 20:15 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 16,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033107 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,452,685 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 26, 2023 Filed May 31, 2023 20:15 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 12,602 | $13.70 | $172,603.29 |
DisclosureSEC source: 0001209191-23-033107 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.58 to $13.915, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 26, 2023 Filed May 31, 2023 20:15 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 12,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033107 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,469,490 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 23,161 | $13.38 | $309,972.93 |
DisclosureSEC source: 0001209191-23-032529 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.20 to $13.65, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 23,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032529 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,482,092 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 7,900 | $13.66 | $107,920.32 |
DisclosureSEC source: 0001209191-23-032529 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 7,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032529 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,505,253 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 23, 2023 Filed May 24, 2023 21:07 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 43,939 | $14.74 | $647,647.68 |
DisclosureSEC source: 0001209191-23-031916 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.41 to $14.935, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 23, 2023 Filed May 24, 2023 21:07 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 43,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031916 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,513,153 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:07 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 87,922 | $14.13 | $1,242,091.68 |
DisclosureSEC source: 0001209191-23-031916 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.335, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:07 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 87,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031916 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,557,092 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 19, 2023 Filed May 22, 2023 20:21 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 63,212 | $13.88 | $877,066.50 |
DisclosureSEC source: 0001209191-23-031450 · doc4.xml · nonDerivative · entry 5 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.30 to $14.03, inclusive. F6 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 19, 2023 Filed May 22, 2023 20:21 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 63,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031450 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,645,014 F4 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 18, 2023 Filed May 22, 2023 20:21 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 14,022 | $13.06 | $183,170.79 |
DisclosureSEC source: 0001209191-23-031450 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.02 to $13.10, inclusive. F6 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 18, 2023 Filed May 22, 2023 20:21 UTC | Prime Medicine, Inc. PRME · Entity 5281 | OtherCommon Stock | 14,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031450 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,708,226 F4 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 18, 2023 Filed May 22, 2023 20:21 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 13,076 | $13.01 | $170,100.45 |
DisclosureSEC source: 0001209191-23-031450 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,722,248 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 and in footnotes 5 and 7 of this Form 4. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 17, 2023 Filed May 18, 2023 20:16 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 15,000 | $12.77 | $191,599.50 |
DisclosureSEC source: 0001209191-23-030621 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,735,324 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.075, inclusive. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:16 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 50,649 | $12.59 | $637,675.97 |
DisclosureSEC source: 0001209191-23-030621 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,750,324 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.465 to $12.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 and in footnote 4 of this Form 4. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:16 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 157,952 | $12.74 | $2,012,087.35 |
DisclosureSEC source: 0001209191-23-029789 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,800,973 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.60 to $12.97, inclusive. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:16 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 27,290 | $12.72 | $347,221.59 |
DisclosureSEC source: 0001209191-23-029789 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,958,925 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.65 to $13.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 and in footnote 4 of this Form 4. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:16 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 4,807 | $13.79 | $66,289.97 |
DisclosureSEC source: 0001209191-23-029033 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,986,215 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.00, inclusive. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:16 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 21,819 | $12.98 | $283,243.35 |
DisclosureSEC source: 0001209191-23-029033 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,991,022 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $13.49, inclusive. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:16 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 87,397 | $14.03 | $1,225,804.10 |
DisclosureSEC source: 0001209191-23-029033 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 11,012,841 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 and in footnotes 4 and 5 of this Form 4. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 09, 2023 Filed May 10, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 321,238 | $14.08 | $4,522,613.43 |
DisclosureSEC source: 0001209191-23-028464 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 11,100,238 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.215, inclusive. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 08, 2023 Filed May 10, 2023 20:17 UTC | Prime Medicine, Inc. PRME · Entity 5281 | SaleCommon Stock | 100,772 | $14.13 | $1,423,726.97 |
DisclosureSEC source: 0001209191-23-028464 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 11,421,476 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 and in footnote 4 of this Form 4. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:18 UTC | Gitlab Inc. GTLB · Entity 3663 | PurchaseClass A Common Stock | 7,286 | $26.98 | $196,583.57 |
DisclosureSEC source: 0001209191-23-028245 · doc4.xml · nonDerivative · entry 1 GV 2021 GP, L.L.C. · CIK 0001861206 · Member of 10% Group GV 2021 GP, L.P. · CIK 0001861216 · Member of 10% Group GV 2021, L.P. · CIK 0001861202 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2021, L.P. Disclosed balance after: 2,647,312 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.86 to $27.00, inclusive. The reporting persons undertake to provide to GitLab Inc., any security holder of GitLab Inc., or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1 of this Form 4. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "Partnership"). GV 2021 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2021 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the Partnership. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:44 UTC | Gitlab Inc. GTLB · Entity 3663 | PurchaseClass A Common Stock | 2,168 | $28.26 | $61,263.34 |
DisclosureSEC source: 0001209191-23-027711 · doc4.xml · nonDerivative · entry 5 GV 2021 GP, L.L.C. · CIK 0001861206 · Member of 10% Group GV 2021 GP, L.P. · CIK 0001861216 · Member of 10% Group GV 2021, L.P. · CIK 0001861202 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2021, L.P. Disclosed balance after: 2,640,026 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.2505 to $28.26, inclusive. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "Partnership"). GV 2021 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2021 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the Partnership. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:44 UTC | Gitlab Inc. GTLB · Entity 3663 | PurchaseClass A Common Stock | 91,710 | $27.65 | $2,535,983.26 |
DisclosureSEC source: 0001209191-23-027711 · doc4.xml · nonDerivative · entry 4 GV 2021 GP, L.L.C. · CIK 0001861206 · Member of 10% Group GV 2021 GP, L.P. · CIK 0001861216 · Member of 10% Group GV 2021, L.P. · CIK 0001861202 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2021, L.P. Disclosed balance after: 2,637,858 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.25 to $28.2447, inclusive. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "Partnership"). GV 2021 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2021 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the Partnership. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:44 UTC | Gitlab Inc. GTLB · Entity 3663 | PurchaseClass A Common Stock | 302,483 | $26.75 | $8,092,418.44 |
DisclosureSEC source: 0001209191-23-027711 · doc4.xml · nonDerivative · entry 3 GV 2021 GP, L.L.C. · CIK 0001861206 · Member of 10% Group GV 2021 GP, L.P. · CIK 0001861216 · Member of 10% Group GV 2021, L.P. · CIK 0001861202 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2021, L.P. Disclosed balance after: 2,546,148 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.25 to $27.2498, inclusive. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "Partnership"). GV 2021 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2021 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the Partnership. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:44 UTC | Gitlab Inc. GTLB · Entity 3663 | PurchaseClass A Common Stock | 22,461 | $28.95 | $650,306.59 |
DisclosureSEC source: 0001209191-23-027711 · doc4.xml · nonDerivative · entry 2 GV 2021 GP, L.L.C. · CIK 0001861206 · Member of 10% Group GV 2021 GP, L.P. · CIK 0001861216 · Member of 10% Group GV 2021, L.P. · CIK 0001861202 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2021, L.P. Disclosed balance after: 2,243,665 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.82 to $29.00, inclusive. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "Partnership"). GV 2021 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2021 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the Partnership. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:44 UTC | Gitlab Inc. GTLB · Entity 3663 | PurchaseClass A Common Stock | 287,470 | $28.30 | $8,134,021.14 |
DisclosureSEC source: 0001209191-23-027711 · doc4.xml · nonDerivative · entry 1 GV 2021 GP, L.L.C. · CIK 0001861206 · Member of 10% Group GV 2021 GP, L.P. · CIK 0001861216 · Member of 10% Group GV 2021, L.P. · CIK 0001861202 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By GV 2021, L.P. Disclosed balance after: 2,221,204 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.82 to $28.81, inclusive. The reporting persons undertake to provide to GitLab Inc., any security holder of GitLab Inc., or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1 and in footnotes 3 through 6 of this Form 4. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "Partnership"). GV 2021 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2021 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the Partnership. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 21:43 UTC | Gitlab Inc. GTLB · Entity 3663 | PurchaseClass A Common Stock | 55,051 | $30.97 | $1,704,808.36 |
DisclosureSEC source: 0001209191-23-018969 · doc4.xml · nonDerivative · entry 6 GV 2021 GP, L.L.C. · CIK 0001861206 · Member of 10% Group GV 2021 GP, L.P. · CIK 0001861216 · Member of 10% Group GV 2021, L.P. · CIK 0001861202 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2021, L.P. Disclosed balance after: 1,933,734 F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.65 to $31.00, inclusive. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "Partnership"). GV 2021 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2021 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the Partnership. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 21:43 UTC | Gitlab Inc. GTLB · Entity 3663 | PurchaseClass A Common Stock | 169,156 | $30.30 | $5,125,934.27 |
DisclosureSEC source: 0001209191-23-018969 · doc4.xml · nonDerivative · entry 5 GV 2021 GP, L.L.C. · CIK 0001861206 · Member of 10% Group GV 2021 GP, L.P. · CIK 0001861216 · Member of 10% Group GV 2021, L.P. · CIK 0001861202 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2021, L.P. Disclosed balance after: 1,878,683 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.61 to $30.50, inclusive. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "Partnership"). GV 2021 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2021 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the Partnership. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 21:43 UTC | Gitlab Inc. GTLB · Entity 3663 | PurchaseClass A Common Stock | 16,013 | $30.99 | $496,310.12 |
DisclosureSEC source: 0001209191-23-018969 · doc4.xml · nonDerivative · entry 4 GV 2021 GP, L.L.C. · CIK 0001861206 · Member of 10% Group GV 2021 GP, L.P. · CIK 0001861216 · Member of 10% Group GV 2021, L.P. · CIK 0001861202 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2021, L.P. Disclosed balance after: 1,709,527 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.95 to $31.00, inclusive. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "Partnership"). GV 2021 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2021 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the Partnership. Each of the GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.